[A case of drug resistant recurrent gastrointestinal stromal tumor treated surgically by resection, partial hepatectomy and diaphragmectomy].

Abstract

This 69-year-old man underwent a partial jejunectomy for gastrointestinal stromal tumor(GIST) at the age of 60, and subsequently hepatectomy of segment 5, 6, 7 for liver metastasis of GIST a year later. An irregular mass close to the cutting stump of the liver, and a mass that showed enhanced-effect at segment 4 was discovered 28 months after hepatectomy. In order to treat this second recurrence, we administered imatinib and sunitinib sequentially. The tumor subsequently became drug-resistant, so we removed it surgically together with the liver and a portion of right diaphragm, and a tumor in segment 4. The patient shows no recurrent sign 4 months after surgery. This case suggests that surgical resection should be considered for partially drug resistant GIST.

• Authors: Nobuhiko Ueda, Emi Morioka, Daisuke Kaida, Yasuto Tomita, Toshio Ohnishi, Yukako Ohno, Miki Noguchi, Hiroshi Funaki, Shinichi Kinami, Kazuhiko Omote, Yasuharu Nakano, Takeo Kosaka, Satoko Nakata, Hiroshi Minato, Hiroyuki Takamura
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 39 Issue 12 Pg. 2438-40 (Nov 2012) ISSN: 0385-0684 [Print] Japan
• PMID: 23268103 (Publication Type: Case Reports, Journal Article)

Chemical References

• Benzamides
• Indoles
• Piperazines
• Pyrimidines
• Pyrroles
• Imatinib Mesylate
• Sunitinib

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Benzamides
• Combined Modality Therapy
• Diaphragm (surgery)
• Drug Resistance, Neoplasm
• Gastrointestinal Stromal Tumors (drug therapy, surgery)
• Hepatectomy
• Humans
• Imatinib Mesylate
• Indoles (administration & dosage)
• Jejunal Neoplasms (drug therapy, surgery)
• Liver Neoplasms (secondary, surgery)
• Male
• Peritoneal Neoplasms (secondary, surgery)
• Piperazines (administration & dosage)
• Pyrimidines (administration & dosage)
• Pyrroles (administration & dosage)
• Recurrence
• Sunitinib